foxo4-dri senolytic or senomorphic Class II senolytics inhibit survival pathways elicited by senescent FOXO4-DRI Dosing: 1mg Senolytic Protocol
FOXO4 DRI Dosing: 1mg Senolytic Protocol (2026) Cleara Biotech senolytic candidate FOXO4 DRI The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data
Pay in 4 interest-free payments of $5.30 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8



